Maglira 5 (semaglutide)

Maglira 5 contains the GLP-1 agonist semaglutide, designed to activate the gluco­gon-like peptide-1 receptor, which helps reduce appetite, slow gastric emptying and support metabolic regulation.
Packaged in a convenient pre-filled pen format, Maglira 5 is built for ease of use in a weekly regimen.

Key Benefits

• Supports appetite reduction and manageable portion control — excellent for clients focused on fat-loss and body composition change.

• Weekly injectable format: Simplifies commitment and consistency for busy lifestyles.

• Complements a holistic lifestyle approach: Nutrition, resistance training, and good sleep amplify results.

• Precision dosing with pre-filled pen ensures cleanliness, convenience and accurate administration.

Product Specifications

• Active Ingredient: Semaglutide

• Strength: 5 mg total per pen (pre-filled)

• Format: Pre-filled injection pen (weekly use)

• Administration: Sub-cutaneous injection (abdomen, thigh or upper arm)

• Storage: Refrigerate unopened (2-8 °C), follow manufacturer instructions for in-use storage.

• Intended Use: For adults under appropriate supervision, as part of a structured weight-management or metabolic support programme.

How to Use

1. Consult a qualified healthcare practitioner before starting — baseline assessment is essential.

2. Begin with the prescribed starting dose, then progress according to tolerance and response in coordination with your practitioner.

3. Administer once weekly, consistently on the same day each week, and rotate injection sites.

4. Pair with a nutrient-dense diet, resistance training regime and proper hydration for optimal effect.

5. Monitor progress: tracked body-weight, energy levels, appetite changes, and any tolerability issues.

Safety & Considerations

• Use only under medical supervision. Semaglutide-based therapies are regulated; in South Africa, the regulatory body SAHPRA has cautioned about quality and legitimacy of unregistered GLP-1 products.

• Possible side-effects (based on GLP-1 class drugs): nausea, vomiting, constipation, changes in digestion, possible gallbladder effects, or pancreas-related risks. Gradual dose increase helps mitigate.

• Not a substitute for lifestyle — diet and exercise remain foundational.

• Not suitable for everyone: Contra-indications may include certain thyroid conditions, pancreatitis history, or type 1 diabetes.

Disclaimer: This product is supplied strictly for laboratory research purposes only. Not intended for human or animal consumption. Not a medicine.